Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 466 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Primary Lateral Sclerosis Clear all
Completed No phase listed Observational Accepts healthy volunteers

Genetics of Pediatric-Onset Motor Neuron and Neuromuscular Diseases

NCT02532244
View directory record Official record
Conditions
Spinal Muscular Atrophy, Charcot-Marie-Tooth Disease, Muscular Dystrophy, Spinal Muscular Atrophy With Respiratory Distress 1, Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Neuromuscular Disease, Peroneal Muscular Atrophy
Interventions
sample collection
Other
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
1 Month and older
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2024
U.S. locations
3
States / cities
Wilmington, Delaware • Jacksonville, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Oct 21, 2026, 6:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Olfactory Deficits in Neurologic Disease

NCT05019014
View directory record Official record
Conditions
Alzheimer Disease, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Lewy Body Disease, Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 21, 2026, 6:40 PM EDT
Completed No phase listed Observational

Brain Function in Primary Lateral Sclerosis and Amyotrophic Lateral Sclerosis

NCT00334516
View directory record Official record
Conditions
Cerebral Cortex Dysfunction
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2019 · Synced Oct 21, 2026, 6:40 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study of [11C]CPPC to Assess the Safety and Tolerability in Patients With ALS

NCT04749433
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
[11C]CPPC Injection
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 21, 2026, 6:40 PM EDT
Completed Phase 2 Interventional Results available

Multiple Doses of AT-1501-A201 in Adults With ALS

NCT04322149
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
AT-1501
Drug
Lead sponsor
Anelixis Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Phoenix, Arizona • Orange, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 21, 2026, 6:40 PM EDT
Completed Phase 2 Interventional

Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT00072709
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
TCH346
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
21 Years to 80 Years
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 24, 2011 · Synced Oct 21, 2026, 6:40 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

A Longitudinal Analysis of Biomarkers in Patients With ALS

NCT05309408
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Venipuncture, Lumbar Puncture
Diagnostic Test
Lead sponsor
Holy Cross Hospital, Florida
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Sep 22, 2023 · Synced Oct 21, 2026, 6:40 PM EDT
Completed Phase 1 Interventional

Open Label Study: Treatment of ALS Fatigue With PolyMVA

NCT04557410
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
PolyMVA
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Oct 21, 2026, 6:40 PM EDT
Recruiting Phase 3 Interventional

Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

NCT07322003
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Pridopidine, Placebo
Drug
Lead sponsor
Prilenia
Industry
Eligibility
18 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
18
States / cities
Phoenix, Arizona • San Francisco, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 21, 2026, 6:40 PM EDT
Terminated Phase 1Phase 2 Interventional

Study to Evaluate Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Appendicular Muscle in Adult Subjects With ALS

NCT03334786
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Fasciculation
Interventions
FLX-787-ODT
Drug
Lead sponsor
Flex Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 21, 2026, 6:40 PM EDT
Completed Phase 2 Interventional Results available

Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT01786603
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Rasagiline, Placebo
Drug
Lead sponsor
Richard Barohn, MD
Other
Eligibility
21 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
10
States / cities
Phoenix, Arizona • Irvine, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 21, 2026, 6:40 PM EDT
Completed No phase listed Observational

Study of ALS Reversals 4: LifeTime Exposures

NCT03706391
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Progressive Muscular Atrophy, Motor Neuron Disease
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
25 participants
Timeline
2018 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Oct 21, 2026, 6:40 PM EDT
Completed Phase 1 Interventional

A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis

NCT05006352
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
DNL343, Placebo
Drug
Lead sponsor
Denali Therapeutics Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
6
States / cities
Scottsdale, Arizona • San Diego, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 21, 2026, 6:40 PM EDT
Recruiting Not applicable Interventional

Do Video Recordings of Multidisciplinary Clinics Improve Quality of Life for People With ALS and Their Caregivers?

NCT07454733
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Video recording, Notes Instruction
Behavioral
Lead sponsor
Trustees of Dartmouth College
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
7
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 21, 2026, 6:40 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

NCT04363684
View directory record Official record
Conditions
Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis, Oligosymptomatic PSP (oPSP), C9orf72, GRN Related Frontotemporal Dementia, MAPT Gene Mutation, TBK1 Gene Mutation, Oligosymptomatic Progressive Supranuclear Palsy
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2030
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 21, 2026, 6:40 PM EDT
Recruiting No phase listed Observational

NYSCF Scientific Discovery Biobank

NCT06203106
View directory record Official record
Conditions
ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder
Interventions
Biological Sample Collection
Other
Lead sponsor
New York Stem Cell Foundation Research Institute
Other
Eligibility
30 Days and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2045
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 21, 2026, 6:40 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of AMDX-2011P as a Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy

NCT05542576
View directory record Official record
Conditions
Parkinson Disease, Amyotrophic Lateral Sclerosis
Interventions
AMDX2011P
Drug
Lead sponsor
Amydis Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Newport Beach, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Oct 21, 2026, 6:40 PM EDT
Completed No phase listed Observational

A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers

NCT01495390
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Nervous System Diseases, Sclerosis, Motor Neuron Disease, Spinal Cord Diseases, Central Nervous System Diseases, Neurodegenerative Diseases, Neuromuscular Diseases, ALS
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
6
States / cities
Phoenix, Arizona • Jacksonville, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 21, 2026, 6:40 PM EDT
Not yet recruiting Not applicable Interventional

Augmented Reality BCI Longitudinal Study for Persons With ALS, Stroke, TBI and SCI Utilizing Cognixion + Apple Vision Pro

NCT07209943
View directory record Official record
Conditions
ALS (Amyotrophic Lateral Sclerosis), TBI Traumatic Brain Injury, SCI - Spinal Cord Injury, Stroke
Interventions
Cognixion + Apple Vision Pro
Device
Lead sponsor
Cognixion
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 21, 2026, 6:40 PM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

NCT03127267
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Masitinib (6.0), Riluzole, Placebo, Masitinib (4.5)
Drug
Lead sponsor
AB Science
Industry
Eligibility
18 Years to 81 Years
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 21, 2026, 6:40 PM EDT
Completed Not applicable Interventional Results available

The Use of Airway Clearance Devices in ALS

NCT02682030
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
High Frequency Chest Compression Device (HFCC), Cough Assist
Device
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Oct 21, 2026, 6:40 PM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Personalized Antisense Oligonucleotide Therapy for a Participant With TARDBP ALS

NCT07703462
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
nL-TARDB-002
Drug
Lead sponsor
n-Lorem Foundation
Other
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 21, 2026, 6:40 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis

NCT03945279
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
BIIB100, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Phoenix, Arizona • San Diego, California • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 21, 2026, 6:40 PM EDT
Completed No phase listed Observational

Muscle Ultrasound Measures as Biomarkers of Upper Motor Neuron Function

NCT02408900
View directory record Official record
Conditions
Muscle Spasticity
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 21, 2026, 6:40 PM EDT